Essential resources, easily available.

Our e-learning modules, resources and forums provide oncology pharmacy staff with the tools required to stay abreast of the latest developments to improve patient care.

eLearning

  • Field-specific online modules
  • Supporting certification that can be used to support CPD
  • Keep up to date within the field of oncology pharmacy
  • Stop and continue the course at a time that suits you
Explore eLearning

Your community

  • Innovation through collaboration
  • Communicate with other members of the oncology pharmacy network
  • Share documents and links
  • Submit posts quickly and easily on our interactive forums
Explore community

Resources

  • Access to BOPA publications and position statements
  • Links for further reading and information
  • Checked and verified documents ensures material is current
  • Quick downloads
Explore resources

Latest news

By Dr Gerard Walls on 4th August 2025

Controversies in Unresectable Stage III NSCLC Webinar

BOPA has been asked to share with you details of the webinar ‘Controversies in Unresectable Stage III NSCLC’, organised by University of Leeds, on Tuesday 26th August. It is held…

Read article
By BOPA on behalf of ISOPP on 29th July 2025

ISOPP July 2025 Newsletter

Volume 27 | No.7 | July 2025 From Netty Cracknell, ISOPP President Dear BOPA members, This month has been incredibly busy, and while there are moments I feel completely exhausted,…

Read article
By BOPA on 23rd July 2025

Third Annual Cancer Associated Thrombosis Summit: North of England

The NEONC CAT conference returns this year on the 8th of November, in Hull. As the UK’s only dedicated cancer associated thrombosis (CAT) conference, it presents a unique opportunity for…

Read article
By BOPA on 22nd July 2025

BOPA Questionnaire – Monitoring and Treatments for Immune-Related Myocarditis

The BOPA Immunotherapy Specialist Interest Group invites all BOPA members to complete this survey. This builds on our previous work exploring the known disparity across the UK with regards to…

Read article
Further news